Pds biotechnology expands versatile-002 study of pds0101 and keytruda® in advanced head and neck cancer to include patients who have failed prior treatment with checkpoint inhibitors

Florham park, n.j., june 03, 2021 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the company's proprietary versamune® t-cell activating technology, today announced the protocol amendment to expand its phase 2 versatile-002 study to include patients, in an additional arm, who have failed prior checkpoint inhibitor (cpi) therapy (cpi refractory patients). the versatile-002 study is designed to evaluate pds0101 in combination with keytruda® (pembrolizumab) in the treatment of advanced human papillomavirus (hpv)-associated head and neck cancer and is currently being run at approximately 20 clinical sites in the us.
PDSB Ratings Summary
PDSB Quant Ranking